Pharmacology
All Targets
7-TM Receptors
Ion Channels
Nuclear Receptors
Enzyme-Linked Receptors
Transporters
Enzymes
Other Pharmacology
Cellular Processes
Angiogenesis
Apoptosis
Cell Cycle
Cell Metabolism
Cytoskeleton & Motor Proteins
ECM & Adhesion Molecules
Epigenetics 
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Home » Pharmacology » 7-TM Receptors » Glutamate (Metabotropic) Receptors » Glutamate (Metabotropic) Group I Receptors
Glutamate (Metabotropic) Group I Receptors
More Information »Metabotropic glutamate (mGlu) group I receptors are members of the metabotropic class of glutamate receptors, which also includes mGlu group II and mGlu group III receptors. mGlu group I receptors are divided into two subtypes, mGlu1 and mGlu5.
Glutamate (Metabotropic) Group I Receptor Products
Agonists |
|
Cat.No. |
Product Name / Activity |
| 0284 | (1S,3R)-ACPD |
| Group I/group II mGlu agonist | |
| 0187 | (±)-trans-ACPD |
| Group I/group II mGlu agonist | |
| 1049 | CHPG |
| mGlu5 selective agonist | |
| 3695 | CHPG Sodium salt |
| Selective mGlu5 agonist. Sodium salt of CHPG (Cat. No. 1049) | |
| 0342 | (RS)-3,5-DHPG |
| Selective group I mGlu agonist | |
| 0805 | (S)-3,5-DHPG |
| Selective group I mGlu agonist. Active enantiomer of 3,5-DHPG (Cat. No. 0342) | |
| 0324 | (RS)-3-Hydroxyphenylglycine |
| Group I mGlu agonist | |
| 0326 | (S)-3-Hydroxyphenylglycine |
| Group I mGlu agonist, active isomer | |
| 3331 | NPEC-caged-(1S,3R)-ACPD |
| Caged (1S,3R)-ACPD | |
| 2923 | NPEC-caged-(S)-3,5-DHPG |
| Caged (S)-3,5-DHPG (Cat. No. 0805) | |
| 0188 | L-Quisqualic acid |
| Very potent group I mGlu agonist | |
| 0162 | S-Sulfo-L-cysteine sodium salt |
| Group I agonist | |
Antagonists |
|
Cat.No. |
Product Name / Activity |
| 3060 | A 841720 |
| Selective mGlu1 antagonist | |
| 2254 | ACDPP hydrochloride |
| Selective mGlu5 receptor antagonist | |
| 0904 | AIDA |
| Potent, selective group I mGlu antagonist | |
| 0125 | DL-AP3 |
| Group I mGlu antagonist | |
| 2501 | Bay 36-7620 |
| Non-competitive mGlu1 antagonist with inverse agonist activity | |
| 0329 | (S)-3-Carboxy-4-hydroxyphenylglycine |
| Group I antagonist/group II agonist | |
| 0320 | (S)-4-Carboxy-3-hydroxyphenylglycine |
| Group I antagonist/group II agonist | |
| 0323 | (S)-4-Carboxyphenylglycine |
| Competitive group I mGlu antagonist/weak group II agonist | |
| 1028 | CPCCOEt |
| Selective non-competitive mGlu1 receptor antagonist | |
| 1009 | E4CPG |
| Group I/group II mGlu antagonist | |
| 2386 | Fenobam |
| Potent and selective mGlu5 antagonist | |
| 1749 | HexylHIBO |
| Group I mGlu antagonist | |
| 1750 | (S)-HexylHIBO |
| Group I mGlu antagonist | |
| 2333 | JNJ 16259685 |
| Extremely potent, mGlu1-selective non-competitive antagonist | |
| 1237 | LY 367385 |
| Selective mGlu1a antagonist | |
| 2390 | LY 456236 hydrochloride |
| Selective mGlu1 antagonist | |
| 2196 | 3-MATIDA |
| Potent, selective mGlu1 antagonist | |
| 3696 | (RS)-MCPG disodium salt |
| Sodium salt of (RS)-MCPG (Cat. No. 0336) | |
| 0336 | (RS)-MCPG |
| Non-selective mGlu antagonist | |
| 0337 | (S)-MCPG |
| Non-selective mGlu antagonist. Active isomer of Cat. No. 0336 | |
| 1212 | MPEP hydrochloride |
| mGlu5 antagonist and positive allosteric modulator at mGlu4 | |
| 2921 | MTEP hydrochloride |
| Potent, selective mGlu5 antagonist | |
| 4134 | NPS 2390 |
| Group I mGlu antagonist | |
| 1027 | PHCCC |
| Potent group I mGlu antagonist | |
| 1215 | SIB 1757 |
| Highly selective mGlu5 antagonist | |
| 1214 | SIB 1893 |
| mGlu5 antagonist and positive allosteric modulator at mGlu4 | |
| 3413 | YM 202074 |
| High affinity, selective mGlu1 antagonist | |
| 2986 | YM 230888 |
| Selective mGlu1 antagonist | |
| 2448 | YM 298198 hydrochloride |
| Highly potent, selective non-competitive mGlu1 antagonist | |
| 2447 | Desmethyl-YM 298198 |
| Derivative of mGlu1 antagonist YM 298198 (Cat. No. 2448) | |
Modulators |
|
Cat.No. |
Product Name / Activity |
| 4416 | ADX 10059 hydrochloride |
| Negative allosteric modulator at mGlu5 | |
| 3235 | CDPPB |
| Positive allosteric modulator at mGlu5 | |
| 1952 | DCB |
| Allosteric modulator at mGlu5 | |
| 1625 | DFB |
| Allosteric potentiator at mGlu5 | |
| 1953 | DMeOB |
| Negative allosteric modulator at mGlu5 | |
| 4438 | MFZ 10-7 |
| Negative allosteric modulator at mGlu5 | |
| 4348 | Ro 01-6128 |
| Positive allosteric modulator of mGlu1 | |
| 4347 | Ro 67-4853 |
| Positive allosteric modulator of group I mGlu receptors | |
| 4346 | Ro 67-7476 |
| Positive allosteric modulator of mGlu1 | |
| 4381 |
VU 0285683
|
| Negative allosteric modulator at mGlu5 | |
| 4437 | VU 0357121 |
| Positive allosteric modulator of mGlu5 | |
| 4323 | VU 0360172 hydrochloride |
| Positive allosteric modulator at mGlu5 | |
| 4394 | VU 0360223 |
| Negative allosteric modulator at mGlu5 | |
| 3325 | VU 1545 |
| mGlu5 positive allosteric modulator | |
| 4458 | VU 29 |
| Potent mGlu5 allosteric potentiator | |
Ligand Sets |
|
Cat.No. |
Product Name / Activity |
| 1826 | Group I mGlu Receptor Tocriset™ |
| Selection of 5 group I mGlu receptor ligands (Cat. Nos. 0805, 0188, 1237, 1212 and 0337) | |
| 1829 | Mixed mGlu Receptor Tocriset™ |
| Selection of 5 mixed mGlu receptor ligands (Cat. Nos. 0805, 0975, 0103, 0337 and 1209) | |
Related Categories
Quick Order
Find multiple products by catalog number
Pain Research Guide
Reserve your free copy
Highlights over 280 products for Pain research. Reserve copy
mGlu Receptors Review
Written by Francine Acher, an expert in the field. Request a copy or view PDF today.
Neurobiology of Parkinson's Disease
Written by A. Schapira
'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
Antidepressants - Current and Future Targets
Written by P. Skolnich et al
'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.
Tocris Events
Win a Kindle
5th Conference on Advances in Molecular Mechanisms Underlying Neurological Disorders
June 23 - 26, 2013
Bath, UK